These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17133204)

  • 21. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
    Gulick RM; Ribaudo HJ; Shikuma CM; Lalama C; Schackman BR; Meyer WA; Acosta EP; Schouten J; Squires KE; Pilcher CD; Murphy RL; Koletar SL; Carlson M; Reichman RC; Bastow B; Klingman KL; Kuritzkes DR;
    JAMA; 2006 Aug; 296(7):769-81. PubMed ID: 16905783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania.
    Ramadhani HO; Thielman NM; Landman KZ; Ndosi EM; Gao F; Kirchherr JL; Shah R; Shao HJ; Morpeth SC; McNeill JD; Shao JF; Bartlett JA; Crump JA
    Clin Infect Dis; 2007 Dec; 45(11):1492-8. PubMed ID: 17990233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.
    Eron JJ; Yetzer ES; Ruane PJ; Becker S; Sawyer GA; Fisher RL; Tolson JM; Shaefer MS
    AIDS; 2000 Apr; 14(6):671-81. PubMed ID: 10807190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
    Nadler JP; Gathe JC; Pollard RB; Richmond GJ; Liao Q; Griffith S; Lancaster CT; Hernandez JE; Pappa KA;
    BMC Infect Dis; 2003 Jun; 3():10. PubMed ID: 12795812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The feasibility of a community-based directly administered antiretroviral therapy program.
    Wohl AR; Garland WH; Squires K; Witt M; Larsen R; Kovacs A; Hader S; Weidle PJ
    Clin Infect Dis; 2004 Jun; 38 Suppl 5():S388-92. PubMed ID: 15156427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virologic outcome among patients receiving antiretroviral therapy at five hospitals in Haiti.
    Jean Louis F; Buteau J; François K; Hulland E; Domerçant JW; Yang C; Boncy J; Burris R; Pelletier V; Wagar N; Deyde V; Lowrance DW; Charles M
    PLoS One; 2018; 13(1):e0192077. PubMed ID: 29381736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use.
    Palepu A; Tyndall M; Yip B; O'Shaughnessy MV; Hogg RS; Montaner JS
    J Acquir Immune Defic Syndr; 2003 Apr; 32(5):522-6. PubMed ID: 12679704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.
    Vidal C; García F; Gatell JM; Leal M; Clotet B; Pumarola T; Miró JM; Mallolas J; Ruiz L; Cruceta A; Tortajada C
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Sep; 19(1):55-60. PubMed ID: 9732070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group.
    Haubrich RH; Little SJ; Currier JS; Forthal DN; Kemper CA; Beall GN; Johnson D; Dubé MP; Hwang JY; McCutchan JA
    AIDS; 1999 Jun; 13(9):1099-107. PubMed ID: 10397541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Directly observed antiretroviral therapy to reduce genital tract and plasma HIV-1 RNA in women with poor adherence.
    Harwell JI; Flanigan TP; Mitty JA; Macalino GE; Caliendo AM; Ingersoll J; Stenzel MS; Carpenter CC; Cu-Uvin S
    AIDS; 2003 Sep; 17(13):1990-3. PubMed ID: 12960835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rationale, design, and sample characteristics of a randomized controlled trial of directly observed antiretroviral therapy delivered in methadone clinics.
    Berg KM; Mouriz J; Li X; Duggan E; Goldberg U; Arnsten JH
    Contemp Clin Trials; 2009 Sep; 30(5):481-9. PubMed ID: 19505589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
    Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A
    Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics.
    Parczewski M; Siwak E; Leszczyszyn-Pynka M; Cielniak I; Burkacka E; Pulik P; Witor A; Muller K; Zasik E; Grzeszczuk A; Jankowska M; Lemańska M; Olczak A; Grąbczewska E; Szymczak A; Gąsiorowski J; Szetela B; Bociąga-Jasik M; Skwara P; Witak-Jędra M; Jabłonowska E; Wójcik-Cichy K; Kamerys J; Janczarek M; Krankowska D; Mikuła T; Kozieł K; Bielec D; Stempkowska J; Kocbach A; Błudzin W; Horban A
    J Int AIDS Soc; 2017 Jul; 20(1):21847. PubMed ID: 28715160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.
    Demeter LM; Hughes MD; Coombs RW; Jackson JB; Grimes JM; Bosch RJ; Fiscus SA; Spector SA; Squires KE; Fischl MA; Hammer SM
    Ann Intern Med; 2001 Dec; 135(11):954-64. PubMed ID: 11730396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baseline antiretroviral resistance mutations and treatment-emergent resistance in HIV-1 RNA-suppressed patients switching to EVG/COBI/FTC/TDF or continuing on their PI-, NNRTI-, or RAL-based regimen.
    Andreatta K; Kulkarni R; Abram ME; Nguyen T; Cao H; Miller MD; White KL
    J Acquir Immune Defic Syndr; 2015 Apr; 68(5):519-26. PubMed ID: 25559592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial.
    Gallant J; Moyle G; Berenguer J; Shalit P; Cao H; Liu YP; Myers J; Rosenblatt L; Yang L; Szwarcberg J
    Curr HIV Res; 2017; 15(3):216-224. PubMed ID: 27774892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial.
    Davey RT; Murphy RL; Graziano FM; Boswell SL; Pavia AT; Cancio M; Nadler JP; Chaitt DG; Dewar RL; Sahner DK; Duliege AM; Capra WB; Leong WP; Giedlin MA; Lane HC; Kahn JO
    JAMA; 2000 Jul; 284(2):183-9. PubMed ID: 10889591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users.
    Macalino GE; Hogan JW; Mitty JA; Bazerman LB; Delong AK; Loewenthal H; Caliendo AM; Flanigan TP
    AIDS; 2007 Jul; 21(11):1473-7. PubMed ID: 17589194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.